Fred R. Hirsch

Fred R. Hirsch's AcademicInfluence.com Rankings

Fred R. Hirsch

Medical

#1558

World Rank

#1909

Historical Rank

Oncology

#66

World Rank

#70

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Fred R. Hirsch Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Fred R. Hirsch's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) (3193)
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. (2015) (2865)
Lung cancer: current therapies and new targeted treatments (2017) (1910)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. (2005) (1575)
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. (2003) (1402)
Expected performance of the ATLAS experiment - detector, trigger and physics (2008) (1202)
PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project (2017) (1038)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. (2006) (736)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology (2018) (669)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. (2018) (629)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer (2017) (603)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. (2011) (600)
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. (2005) (589)
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. (2006) (565)
PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 Project (2018) (525)
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. (2006) (504)
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. (2000) (452)
Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC (2018) (445)
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. (2015) (402)
Measurement of the azimuthal anisotropy for charged particle production in √ sNN = 2.76 TeV lead-lead collisions with the ATLAS detector (2012) (390)
Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. (2001) (390)
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. (2006) (378)
Combined search for the Standard Model Higgs boson using up to 4.9 fb[superscript −1] of pp collision data at √s = 7 TeV with the ATLAS detector at the LHC (2012) (374)
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. (2005) (371)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors (2021) (364)
New and emerging targeted treatments in advanced non-small-cell lung cancer (2016) (338)
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. (2007) (303)
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. (2008) (300)
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. (2009) (298)
High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. (2002) (294)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. (2018) (294)
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop (2010) (289)
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. (2006) (289)
Epidermal growth factor receptor family in lung cancer and premalignancy. (2002) (288)
Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. (2005) (284)
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. (2005) (263)
The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. (2002) (254)
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer (2009) (252)
The Biology of Epidermal Growth Factor Receptor in Lung Cancer (2004) (252)
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. (2008) (247)
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? (2015) (244)
Staging and prognostic factors in small cell lung cancer: a consensus report (1989) (227)
Histopathologic classification of small cell lung cancer changing concepts and terminology (1988) (221)
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas (2002) (220)
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. (2008) (219)
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. (2009) (218)
Measurement of the inclusive W± and Z/γ∗ cross sections in the e and μ decay channels in pp collisions at √s=7TeV with the ATLAS detector (2012) (210)
Scientific Advances in Lung Cancer 2015 (2016) (207)
The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. (2008) (205)
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. (2003) (204)
PD‐L1 Expression in Lung Cancer (2016) (203)
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 (2015) (199)
The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review (2008) (197)
Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. (2001) (194)
EGFR testing in lung cancer is ready for prime time. (2009) (187)
Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. (2010) (183)
Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. (1980) (183)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. (2018) (182)
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. (2019) (182)
Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. (2002) (174)
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. (2016) (174)
LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes (2017) (169)
Classification of lung cancer histology by gold nanoparticle sensors. (2012) (163)
PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee. (2019) (163)
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. (2012) (162)
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1) (2018) (160)
Non-invasive Breath Analysis of Pulmonary Nodules (2012) (158)
Sniffing the unique "odor print" of non-small-cell lung cancer with gold nanoparticles. (2009) (156)
Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications (2009) (155)
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer (2019) (154)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) (2018) (154)
An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators (2014) (152)
TIM-3, a promising target for cancer immunotherapy (2018) (150)
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. (2013) (146)
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins (2013) (145)
FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies (2014) (144)
Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer (2012) (144)
Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer (2011) (144)
Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. (2001) (142)
Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines (2006) (142)
Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. (2015) (142)
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? (2016) (141)
Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria (2006) (140)
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer (2016) (137)
Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. (2002) (136)
Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics (2015) (133)
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib (2019) (133)
IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY. (2020) (132)
Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. (2012) (132)
Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels (2006) (127)
Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. (2010) (127)
Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer (2015) (124)
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. (2015) (120)
Hepatocyte growth factor expression in EGFR-mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. (2011) (120)
Epidermal growth factor receptor inhibition in lung cancer: status 2012. (2013) (119)
Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations (2010) (117)
Consensus Report of the 2015 Weinman International Conference on Mesothelioma (2016) (117)
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? (2016) (116)
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. (2015) (116)
Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. (2009) (115)
“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy (2019) (114)
Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy (1980) (113)
The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the world health organization. A study of 375 consecutive patients (1983) (113)
A Particle Consistent with the Higgs Boson Observed with the ATLAS Detector at the Large Hadron Collider (2012) (109)
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer (2018) (109)
Staging procedures and prognostic features in small cell anaplastic bronchogenic carcinoma. (1978) (108)
Metastatic patterns in small-cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients. (1987) (106)
HER2/neu expression in malignant lung tumors. (2002) (106)
Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. (1978) (105)
The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification (2009) (104)
Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer (2006) (103)
Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers (2011) (98)
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee (2020) (97)
EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. (2020) (97)
PD‐L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer (2017) (97)
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. (2006) (94)
Volatile fingerprints of cancer specific genetic mutations. (2013) (94)
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. (2008) (91)
The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases (2006) (90)
Morphologic variations of small cell lung cancer: A histopathologic study of pretreatment and posttreatment specimens in 104 patients (1986) (90)
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer (2013) (89)
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. (2017) (89)
A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. (2012) (89)
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. (2009) (89)
The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer. (2019) (87)
EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) (2007) (87)
Review of recent advances in fluorescence bronchoscopy in early localization of central airway lung cancer. (2001) (86)
The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer (2014) (86)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. (2019) (82)
The Insulin-Like Growth Factor Pathway in Lung Cancer (2008) (82)
Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. (2013) (82)
Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. (2003) (80)
Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development (2010) (80)
Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer (2011) (80)
Clinicopathologic Features of Advanced Squamous NSCLC. (2016) (80)
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. (2011) (80)
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients (2005) (80)
Intracranial metastases in small cell carcinoma of the lung prognostic aspects (1983) (80)
Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. (1991) (79)
A Grading system for invasive pulmonary adenocarcinoma: a proposal from the IASLC pathology committee. (2020) (78)
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer (2013) (78)
Measurement of upsilon production in 7 TeV pp collisions at ATLAS (2013) (77)
Scientific Advances and New Frontiers in Mesothelioma Therapeutics. (2018) (77)
Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed (2013) (76)
Histopathologic classification of small cell carcinoma of the lung. Comments based on an interobserver examination (1982) (75)
FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers (2015) (73)
The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer (2010) (73)
Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. (2003) (72)
Analysis of c-ErbB1/Epidermal Growth Factor Receptor and c-ErbB2/HER-2 Expression in Bronchial Dysplasia: Evaluation of Potential Targets for Chemoprevention of Lung Cancer (2006) (71)
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation (2018) (71)
Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer (2005) (70)
Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. (2004) (70)
Advances in the biology of lung cancer chemoprevention. (2005) (69)
A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee (2020) (69)
Tumor Mutation Burden: Promises and Challenges A Perspective from the IASLC Pathology Committee. (2020) (68)
MHC class II expression in lung cancer. (2017) (68)
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer (2016) (67)
The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. (2004) (67)
Hormonal polypeptides and amine metabolites in small cell carcinoma of the lung, with special reference to stage and subtypes (1980) (66)
Search for long-lived, heavy particles in final states with a muon and multi-track displaced vertex in proton–proton collisions at √s =7 TeV with the ATLAS detector (2013) (65)
Search for FCNC single top-quark production at √s = 7 TeV with the ATLAS detector (2012) (65)
Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. (1983) (65)
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. (2010) (65)
Role of biomarkers for early detection of lung cancer and chemoprevention (2002) (65)
Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy (2006) (64)
Searches for heavy long-lived sleptons and R-hadrons with the ATLAS detector in pp collisions at √s=7 TeV (2013) (64)
Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. (2005) (62)
Search for Direct Top Squark Pair Production in Final States with One Isolated Lepton, Jets, and Missing Transverse Momentum in √s=7 TeV pp Collisions Using 4.7 fb[superscript -1] of ATLAS Data (2012) (62)
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. (2014) (62)
Epidermal growth factor receptor immunohistochemistry (2008) (62)
Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer (2008) (61)
Correlation of PD‐L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early‐Stage Squamous Cell Lung Carcinoma (2019) (60)
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. (2012) (58)
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. (2018) (58)
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort (2009) (58)
Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. (2014) (57)
Incidence of lung cancer in Denmark: historical and actual status. (1999) (57)
Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How? (2006) (56)
Search for contact interactions and large extra dimensions in dilepton events from pp collisions at √s=7 TeV with the ATLAS detector (2013) (56)
Innovative Clinical Trials: The LUNG‐MAP Study (2015) (55)
A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer (2012) (55)
ROS1 Immunohistochemistry Among Major Genotypes of Non—Small-Cell Lung Cancer (2014) (54)
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
MAGE A3 antigen-specific cancer immunotherapeutic. (2009) (54)
Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma (1993) (54)
Increased Insulin-Like Growth Factor 1 Receptor Protein Expression and Gene Copy Number in Small Cell Lung Cancer (2010) (52)
The Detection of Chromosomal Aneusomy by Fluorescence In situ Hybridization in Sputum Predicts Lung Cancer Incidence (2010) (52)
MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type (2014) (52)
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines (2011) (51)
Chemoprevention of lung cancer--from biology to clinical reality. (2004) (51)
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment (2016) (50)
Bone marrow involvement in small cell anaplastic carcinoma of the lung. Prognostic and therapeutic aspects (1980) (50)
A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). (2014) (48)
cMET Exon 14 Skipping: From the Structure to the Clinic. (2016) (48)
Early detection of lung cancer by using an autoantibody panel in Chinese population (2018) (48)
The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. (2019) (47)
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes (2017) (47)
Targeting BRAF mutations in non-small cell lung cancer. (2019) (46)
Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819 (2012) (46)
Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. (1996) (46)
Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. (2006) (46)
ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). (2009) (44)
Bronchioloalveolar Carcinoma (2004) (44)
Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. (2017) (44)
EGFR Protein Expression in Non–Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor—A Novel Antibody for Immunohistochemistry or AQUA Technology (2011) (43)
Heterogeneity of PD‐L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma (2018) (42)
From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers (2016) (42)
Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present (2004) (41)
The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. (1987) (41)
Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 (2008) (41)
Lung cancer screening by spiral CT. What is the optimal target population for screening trials? (2002) (41)
BILATERAL BONE‐MARROW EXAMINATIONS IN SMALL‐CELL ANAPLASTIC CARCINOMA OF THE LUNG (1979) (40)
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. (2020) (40)
Scientific Advances in Thoracic Oncology 2016. (2017) (39)
Clinical and comparative utility of afatinib in non-small cell lung cancer (2014) (39)
Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. (2008) (39)
Comprehensive Analysis of EGFR‐Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations (2017) (38)
Treatment of small-cell carcinoma of the lung monitored by sequential flow cytometric DNA analysis. (1982) (38)
Contributions of KRAS and RAL in Non–Small-Cell Lung Cancer Growth and Progression (2013) (38)
Clinical and Biological Basis of Lung Cancer Prevention. (1999) (38)
Early detection and screening of lung cancer (2010) (37)
Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression (1999) (37)
The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consecutive patients with advanced disease (1988) (37)
Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib (2005) (37)
Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma (2012) (36)
Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution (2020) (36)
Sputum Cytologic Atypia Predicts Incident Lung Cancer: Defining Latency and Histologic Specificity (2008) (35)
Recurrent Genomic Gains in Preinvasive Lesions as a Biomarker of Risk for Lung Cancer (2009) (34)
Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. (2013) (33)
Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer. (2007) (33)
Finding ALK-positive lung cancer: what are we really looking for? (2011) (33)
KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer (2009) (33)
EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. (2019) (33)
The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. (2009) (32)
From Expert Review of Molecular Diagnostics (2010) (32)
Staging and Prognosis (1988) (32)
Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodies (1994) (32)
A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce (2019) (32)
Bronchial Epithelial Ki-67 Index Is Related to Histology, Smoking, and Gender, but Not Lung Cancer or Chronic Obstructive Pulmonary Disease (2007) (31)
Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer (2015) (31)
Comparison of characteristics of human small cell carcinoma of the lung in patients, in vitro and transplanted into nude mice. (2009) (31)
Neonatal cancer in Denmark 1943-1985. (1994) (31)
S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. (2009) (31)
PL 03.03 Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples (2017) (30)
High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. (2005) (29)
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer (2021) (29)
Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. (2015) (29)
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. (2019) (29)
Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? (2005) (28)
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial. (2015) (28)
βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer (2012) (28)
Using molecular markers in sputum for the early detection of lung cancer: a review. (2004) (28)
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms (2017) (28)
EGFR‐TKIs plus local therapy demonstrated survival benefit than EGFR‐TKIs alone in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases (2018) (27)
Three‐arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non–small cell lung cancer (NSCLC) patients who will not receive bevacizumab‐based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508) (2012) (27)
Measurement of the inclusive and dijet cross-sections of b-jets in pp collisions at √s = 7 TeV with the ATLAS detector (2011) (27)
Primary Double‐Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench (2017) (27)
CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer (2018) (27)
Efficacy and Safety Results From a Phase II, Placebo‐Controlled Study of Onartuzumab Plus First‐Line Platinum‐Doublet Chemotherapy for Advanced Squamous Cell Non–Small‐Cell Lung Cancer (2017) (27)
Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (2001) (27)
RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer (2017) (27)
A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without α Tocopherol or Observation in Subjects at High Risk for Lung Cancer (2009) (26)
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. (2000) (26)
T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. (2019) (26)
KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. (2009) (26)
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. (2012) (26)
High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts) (2007) (26)
Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung (2017) (26)
Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma (2015) (26)
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). (2020) (25)
Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer (2014) (25)
Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. (2006) (25)
National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers. (2010) (25)
IASLC ATLAS OF EGFR TESTING IN LUNG CANCER (2017) (25)
Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer (2013) (25)
Galectin-9 in non-small cell lung cancer. (2019) (25)
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer (2019) (25)
Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study (2014) (25)
Occurrence of neuron specific enolase in tumour tissue and serum in small cell lung cancer. (1991) (25)
The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis (1994) (25)
Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America (2017) (25)
The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group. (2006) (25)
Independent validation test of the vote-counting strategy used to rank biomarkers from published studies. (2015) (25)
Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). (2004) (25)
B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study (2007) (25)
Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC (2017) (24)
Development of Brain Metastases in Small-Cell Anaplastic Carcinoma of the Lung (1979) (24)
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. (2007) (23)
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536 (2013) (23)
The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations. (2014) (23)
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. (2018) (23)
KRAS G12C-mutant non-small-cell lung cancer: biology, developmental therapeutics, and molecular testing. (2021) (23)
Ancestry-specific predisposing germline variants in cancer (2020) (23)
Increased EGFR gene copy number detected by fish is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126) (2005) (23)
Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis. (1997) (23)
Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib (2009) (23)
Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress? (1997) (22)
Tumor heterogeneity in lung cancer based on light microscopic features (1983) (22)
Low CYP1A2 activity associated with testicular cancer. (2004) (22)
Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective. (2008) (22)
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. (2017) (22)
Genomic Testing in Lung Cancer: Past, Present, and Future. (2018) (21)
Molecular Biomarkers Workshop: a European Strategy for Developing Lung Cancer Molecular Diagnostics in High Risk Populations (2001) (21)
Comprehensive Immune Profiling of Medullary Thyroid Cancer. (2020) (21)
A randomized study of fluorescence bronchoscopy versus white-light bronchoscopy for early detection of lung cancer in high risk patients (2000) (21)
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma (2016) (21)
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation (2017) (20)
Lung Cancer: A multidisciplinary Approach to Diagnosis and Management (2010) (20)
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma. (2017) (20)
Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma (2016) (20)
Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer (2021) (20)
Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines. (2002) (20)
Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. (2002) (20)
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (2015) (19)
Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment‐Naïve Lesions (2017) (19)
Clinical potential of necitumumab in non-small cell lung carcinoma (2016) (19)
Lung cancer chemoprevention: moving from concept to a reality. (2003) (18)
Immunoperoxidase staining for carcinoembryonic antigen in small cell carcinoma of the lung. (1981) (18)
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer (2018) (18)
Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions. (2019) (18)
Consensus for HER2 alterations testing in non-small-cell lung cancer (2022) (18)
c-MET as a biomarker in patients with surgically resected non-small cell lung cancer. (2019) (18)
sLAG-3 in non-small-cell lung cancer patients’ serum (2018) (18)
“Companion Diagnostics”: Has Their Time Come and Gone? (2014) (18)
Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules. (2018) (18)
Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation (2021) (17)
Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention (2012) (17)
Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer (2012) (17)
Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. (1995) (17)
Long non-coding RNA UCA 1 induces non-T 790 M acquired resistance to EGFR-TKIs by activating the AKT / mTOR pathway in EGFR-mutant non-small cell lung cancer (2015) (16)
Lung cancer. Introduction. (2003) (16)
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non–Small-Cell Lung Cancer (2015) (16)
Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy (2008) (16)
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study (2017) (16)
Prevention and early detection of lung cancer-clinical aspects. (1997) (16)
Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP) (2018) (16)
Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer (2015) (15)
IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001. (2002) (15)
Enzastaurin a protein kinase Cbeta-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines. (2006) (15)
Chemoprevention of lung cancer: current status and future prospects. (2003) (15)
Serum Lactate Dehydrogenase and Bone Marrow Metastases in Small-Cell Carcinoma of the Lung (1985) (15)
Review: Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer (2009) (15)
Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients. (2014) (15)
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer (2022) (14)
Recurrent Genomic Gains in Preinvasive Lesions as a Biomarker of Risk for Lung Cancer. (2009) (14)
Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy (2016) (14)
The impact of abdominal computerized tomography on the pretreatment staging and prognosis of small cell lung cancer. (1992) (14)
Targeting Anemia in Patients with Lung Cancer (2006) (14)
Molecular approaches to lung cancer evaluation. (2002) (14)
Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies (2018) (14)
Fluorescence in situ hybridization (FISH) subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in NSCLC (2007) (14)
Expression of target molecules in lung cancer: challenge for a new treatment paradigm. (2002) (14)
What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer? (2002) (13)
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) (2021) (13)
Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status (2017) (13)
Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (Alliance). (2020) (13)
Evaluation of HER2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization (FISH) (2000) (13)
ME1-antibody labelling of primary bronchogenic tumours and extrapulmonary malignancies. (1994) (13)
O-107 FISH and Immunohistochemistry (IHC) can be used to selectNSCLC patients, who will not benefit from gefitinib treatment (2005) (12)
A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). (2019) (12)
Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A. (2015) (12)
Early detection and prevention of lung cancer (2002) (12)
Consensus on medical treatment of non-small cell lung cancer. (2002) (12)
Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines (2017) (12)
The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer (2013) (12)
LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion) (2020) (12)
Search for resonant WZ production in the WZ→lνl′l′ channel in √(s)=7 TeV pp collisions with the ATLAS detector (2012) (11)
Are pathologists biased by clinical information?: A blinded cross-over study of the histopathological diagnosis of mesothelial tumours versus pulmonary adenocarcinoma. (1994) (11)
A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers (2021) (11)
Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients. (2001) (11)
ORAL01.01: A Prospective, Multi‐Institutional Assessment of Four Assays for PD‐L1 Expression in NSCLC by Immunohistochemistry: Topic: Pathology (2016) (11)
Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review). (2014) (11)
Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer (2019) (11)
High prevalence of endobronchial malignancy in high-risk patients with moderate dysplasia in sputum. (2004) (11)
Targeted molecular mechanisms of epoetin alfa. (2003) (11)
Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules (2017) (11)
A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer (2013) (11)
SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay (2016) (11)
Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. (2013) (11)
First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. (2008) (10)
A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. (2012) (10)
EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. (2018) (10)
The International Association for the Study of Lung Cancer Early Lung Imaging Confederation (2020) (10)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma (2022) (10)
Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy‐Naive Isogenic Lung Cancer Lesions with EGFR Mutation (2016) (10)
C225 anti-epidermal growth factor receptor (EGFR) monoclonal antibody sensitizes human non-small cell lung cancer to both radiation and chemotherapy cytotoxicity in-vitro and in-vivo (2001) (10)
Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341) (2007) (10)
Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib (2019) (10)
Serum neuron specific enolase (S-NSE) reference interval evaluation by time-resolved immunofluorometry compared with a radioimmunoassay. (1996) (10)
EGFR IHC and FISH Correlative Analyses (SQUIRE Trial): necitumumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin in 1st-line squamous NSCLC (2015) (10)
Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. (2013) (10)
Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. (2011) (10)
Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naive advanced NSCLC: Correlation of biomarker status and clinical benefit. (2016) (10)
A histopathologic evaluation of premalignant and early malignant bronchial lesions: An interactive program based on internet digital images to improve WHO criteria for early diagnosis of lung cancer and for monitoring chemoprevention studies—A SPORE collaborative project (2000) (10)
Original article: Combination chemotheraphy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens (1991) (9)
Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases. (2019) (9)
EGFR tyrosine kinase inhibitors in squamous cell lung cancer. (2015) (9)
Future developments in the treatment of lung cancer. (2002) (9)
OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer (2019) (9)
OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study (2018) (9)
Staging procedures in small cell lung cancer (1989) (9)
Chemoprevention strategies for non-small cell lung cancer (2002) (9)
Epidermal Growth Factor Receptor Inhibition in Lung Cancer (2013) (9)
Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Small Cell Lung Cancers (2021) (9)
Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study (2022) (8)
An immunohistochemical investigation of diagnostic biopsy material taken from short and long term survivors with small cell lung cancer. (1992) (8)
Epidemiology of lung cancer : a general update. (2002) (8)
Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries. (2017) (8)
Monoclonal antibodies in the detection of bone marrow metastases in small cell lung cancer. (1992) (8)
194PPREVALENCE AND PROGNOSTIC SIGNIFICANCE OF SODIUM-DEPENDENT PHOSPHATE TRANSPORTER 2B (NAPI2B) PROTEIN EXPRESSION IN NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (8)
EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. (2014) (7)
EGFR: a prognostic and/or a predictive marker? (2006) (7)
A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). (2019) (7)
A Proposed System Toward Standardizing Surgery-based Treatments for Malignant Pleural Mesothelioma, From the Joint NCI-IASLC-MARF Taskforce. (2019) (7)
Pathologic considerations and standardization in mesothelioma clinical trials. (2019) (7)
Developing CT image-processing tools to accelerate progress in lung cancer drug development. (2006) (7)
The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review (2021) (7)
Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed. (2012) (7)
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non–Small‐cell Lung Cancer: SWOG S0635 and S0636 Trials (2018) (7)
High gene copy number of epidermal growth factor receptor by fluorescence in situ hybridization is frequent in head and neck squamous cell carcinomas and associates with worse recurrence-free survival. (2006) (7)
O-296 Aberrant DNA methylation and sputum atypia predict lung cancer — Preliminary report from the University of Colorado SPORE high risk cohort study (2003) (6)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
Neuroendocrine characteristics in bronchogenic adenocarcinoma and its clinical relevance (1993) (6)
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. (2021) (6)
1st International Lung Cancer Conference in Beijing, October 27-30, 2002. (2003) (6)
Frequency and significance of epidermal growth factor receptor mutations detected by PCR methods in patients with non-small cell lung cancer. (2019) (6)
Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter. (2016) (6)
Treatment of small cell lung cancer: the Copenhagen experience. (1994) (6)
[Mammographic screening in the municipality of Copenhagen. Results of the first screening round]. (1996) (6)
Biomarkers are here to stay for clinical research and standard care. (2010) (6)
Textbook of Prevention and Detection of Early Lung Cancer (2006) (6)
IASLC Global Survey on PD-L1 Testing for Non-Small Cell Lung Cancer. (2021) (6)
Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report. (2007) (6)
Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753). (2019) (6)
Defining gefitinib sensitivity/resistance in non-small cell lung cancer (NSCLC) cell lines by affymetrix gene arrays. (2004) (6)
[Mammography screening in the county of Copenhagen. Results of the first three screening rounds]. (2002) (6)
RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)--Association between EGFR gene copy number and patients' outcome (2008) (6)
Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical T (2019) (6)
Molecularly targeted therapy: when to stop and when to continue? (2010) (6)
Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer (2020) (6)
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis (2022) (6)
Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse (2021) (5)
Consensus on medical treatment of non-small cell lung cancer (2002) (5)
Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC). (2014) (5)
EGFR Inhibitors in the Treatment of Lung Cancer (2007) (5)
Patient selection criteria and the FLEX Study (2009) (5)
Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers (2019) (5)
Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer (2017) (5)
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry (2022) (5)
Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer (2022) (5)
Clinician Perspectives on Current Issues in Lung Cancer Drug Development (2016) (5)
[Neonatal cancer in Denmark 1943-1985]. (1994) (5)
Neuroendocrine characteristics in malignant lung tumors: implications for diagnosis, treatment, and prognosis. (1995) (5)
Comparison the anti-tumor effect of pyrotinib, afatinb and T-DM1 in lung cancer organoids and PDX models with HER2 mutation. (2018) (5)
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee. (2022) (5)
SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC). (2019) (5)
The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC (2009) (5)
The International Association for the Study of Lung Cancer (IASLC) Molecular Database Project: Objectives, Challenges and Opportunities. (2021) (5)
Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126 (2008) (5)
The aryl hydrocarbon receptor repressor (2008) (5)
Correction: "From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers". (2016) (5)
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations (2022) (5)
88 Oral etoposide (VP-16) every 3 wks. or continuously to elderly patients with small cell lung cancer (SCLC): Preliminary results of a randomized study (1997) (5)
OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D (2017) (5)
Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma (2021) (5)
Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC). (2011) (5)
SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). (2012) (5)
Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer? (2019) (5)
Overcoming resistance to EGFR inhibitors in NSCLC cell lines by sequential treatment with histone deacetylase inhibitors (2005) (5)
SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). (2009) (5)
Chemotherapy: Adjuvant TKIs in NSCLC: what can we learn from RADIANT? (2015) (5)
Epidermal growth factor receptor (EGFR) immunohistochemistry: Comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC) (2007) (4)
Analysis of IGF1R gene copy number by silver in situ hybridization (SISH) in non-small cell lung cancer (NSCLC). (2009) (4)
Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis. (2021) (4)
Studies of pemetrexed and gemcitabine, alone and in combinations, in human lung cancer models. (2006) (4)
Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers (2019) (4)
Forty Years of the International Association for Study of Lung Cancer Pathology Committee (2014) (4)
Treatment of spine metastases in cancer: a review (2019) (4)
P3.12-13 Expression of the Immune Checkpoint Axis-PVR/TIGIT in Small Cell Lung Cancer (2018) (4)
Lung Cancer Fluorescence In Situ Hybridization , Immunohistochemistry , and Next-Generation Sequencing for Detection of EML 4-ALK Rearrangement in Lung Cancer (2015) (4)
Immunocytochemical demonstration of bombesin immunoreactivity in small cell carcinoma of the lung. A methodological study and review of the literature (1990) (4)
Computed tomography screening for lung cancer: what should we recommend? (2001) (4)
Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC. (2016) (4)
Ancestry-specific predisposing germline variants in cancer (2020) (4)
Central Nervous System Metastases in Small Cell Carcinoma of the Lung — A Review (1980) (4)
IASLC Textbook of Prevention and Early Detection of Lung Cancer (2005) (4)
Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases (2016) (4)
Quality of care of patients with non-small-cell lung cancer: a report of a performance improvement initiative. (2014) (4)
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. (2021) (4)
A review of the 5th World Conference on Lung Cancer held by the International Association for the Study of Lung Cancer. (1989) (4)
Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC? (2014) (4)
Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC). (2016) (4)
FASTACT-2: but don't act too fast. (2013) (4)
Loss of STING expression is prognostic in non–small cell lung cancer (2022) (4)
[New techniques for early diagnosis of lung cancer]. (2001) (4)
Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403). (2022) (4)
Insulin-like growth factor receptor 1 (IGF1R) protein expression, mRNA expression and gene copy number in operable non-small cell lung cancer (NSCLC). (2009) (4)
Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum. (2006) (4)
MA04.10 Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC (2018) (3)
Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. (2020) (3)
The role of the pathologist in the clinical management of lung cancer in the 90's (1993) (3)
[Treatment of primary breast cancer. Consequences of mammographic screening in the municipality of Copenhagen]. (1996) (3)
LAG 3/MHC 2 and PD 1/PD L1 expression in non-small cell lung cancer patients. (2016) (3)
OA01.01 Analysis of Lung Cancer Patients Receiving SARS-CoV-2 Vaccines Revealed a Minority Subset With Poor Antibody Responses Relative to Controls (2021) (3)
Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance (2019) (3)
PL02.09 International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials (2021) (3)
1232PSQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY PLUS NECITUMUMAB (IMC-11F8/LY3012211) VS GC ALONE IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC): UPDATE ON KEY SUBGROUPS. (2014) (3)
The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. (2021) (3)
Tumor autoantibodies (TAAs) panel can improve the accuracy of early diagnosis in lung cancer presenting with ground-glass nodules (GGNs) in Chinese population (2018) (3)
Should maintenance chemotherapy be used to treat small cell lung cancer? (1998) (3)
Pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy (RT) for poor-risk stage III non-small cell lung cancer (NSCLC). (2011) (3)
P-272 Angiogenic squamous dysplasia (ASD): A biomarker highly associated with squamous cell lung carcinoma (2003) (3)
3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes (2015) (3)
Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives. (2020) (3)
The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC (3)
Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer (2022) (3)
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. (2021) (3)
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines (2018) (3)
EGFR genomic gain in Japanese non-small cell lung cancer patients treated with gefitinib. (2006) (3)
Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies (2022) (3)
P2-073: High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated patients with non-small cell lung cancer (NSCLC) (2007) (3)
Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials. (2016) (3)
Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non–Small Cell Lung Cancer (2020) (3)
Lack of Association between Sputum Atypia and Chronic Obstructive Pulmonary Disease Mortality (2006) (2)
MA15.03 The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC (2017) (2)
Exploratory biomarker analyses from ECOG 4508: Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients (pts). (2013) (2)
Treatment at the Finsen Institute (1988) (2)
Role of EGFR but not HER2 or HER3 gene copy number in predicting sensitivity of head and neck squamous cell carcinoma (SCCHN) cell lines to EGFR tyrosine kinase inhibitors (2007) (2)
PACIFIC trial: new perspectives for immunotherapy in lung cancer. (2018) (2)
miRNA for Early Detection of Lung Cancer: Comparison of Tissue, Sputum and Plasma Signatures (2017) (2)
Thymidylate synthase (TS) gene copy number in NSCLC. (2010) (2)
International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials (2022) (2)
Histopathology, Ultrastructure, and Cytology (1988) (2)
[Mammographic screening in the county of Copenhagen. Clinical consequences of the first three screening rounds]. (2002) (2)
Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma. (2011) (2)
Physician Bias in Prophylactic Cranial Irradiation Decision Making—An Opportunity for a Patient Decision Aid (2018) (2)
Does lung cancer screening motivate smoking cessation? (2005) (2)
P2.09-24 MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes (2018) (2)
Use of a nanoparticle-based artificial olfactory system, NaNose, to distinguish malignant from benign pulmonary nodules. (2010) (2)
Histological examination for Z-gene alpha 1-antitrypsin deficiency in small cell anaplastic carcinoma of the lung. (1981) (2)
Tobacco money: up in smoke? Authors' reply (2002) (2)
P2.09-24 IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer (2019) (2)
The role of EGFR family in preneoplasia and lung cancer; Perspectives for targeted therapies and selection of patients (2006) (2)
International Association for the Study of Lung Cancer (IASLC): celebrating 40 years with scientific and educational achievements! (2014) (2)
Case Presentation Alk Fusions Are Also Associated with Younger Age Next-generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib- Sensitive Alk Rearrangement in a Patient with Metastatic Non–small-cell Lung Cancer (2012) (2)
Breath analysis as a noninvasive biomarker for early detection of lung cancer. (2014) (2)
Expression of 'small cell carcinoma antigens' in primary small cell lung cancer and metastases: an immunohistochemical study. (1991) (2)
ALK-immunohistochemistry (IHC) standardization with D5F3 antibody in non-small cell lung carcinoma (NSCLC): An international consensus study. (2013) (2)
Potential future consideration for imaging and blood-based biomarkers for precision medicine in lung cancer. (2017) (2)
Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization (2022) (2)
Baseline extracellular vesicle TGF‐β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non–small cell lung cancer (2022) (2)
Validation of proteomic classifier for clinical benefit from erlotinib as first line treatment for advanced non-small cell lung cancer (ECOG 3503) (2007) (2)
CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer. (2021) (2)
MA15.11 Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer (2017) (2)
MA08.10 LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis (2021) (2)
Assessing the association of diabetes with lung cancer risk (2021) (2)
Oral Iloprost For The Chemoprevention Of Lung Cancer (2010) (2)
Risk factors for nicotine dependence in Chinese patients with lung cancer (2018) (2)
Anaplastic lymphoma kinase (ALK): A potential oncogenic driver in triple-negative breast cancer? (2013) (2)
D4-02: Aneusomy by FISH analysis and histology as predictors of invasive lung cancer in bronchial biopsies from high risk subjects (2007) (2)
Measurement of W[superscript +]W[superscript -] production in pp collisions at √s=7 TeV with the ATLAS detector and limits on anomalous WWZ and WWγ couplings (2013) (2)
Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries. (2017) (2)
K-ras mutations in lung cancer: the "mysterious mutation". (2006) (2)
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee (2022) (2)
Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens. (1991) (2)
Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC) (2014) (2)
91 POSTER Development and characterization of predictive markers to the IGF-1R inhibitor, PQIP, in colorectal cancer (CRC) (2008) (1)
Breath Analysis as a Non-invasive Biomarker for Early Detection of Lung Cancer (2014) (1)
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. (2012) (1)
D2-03: Erlotinib (E) as a single agent or intercalated with carboplatin and paclitaxel (ECP) in an EGFR biomarker-selected, previously untreated NSCLC population (2007) (1)
Epidermal growth factor receptor (EGFR) gene amplification in non-small cell lung cancer (NSCLC): molecular patterns and sensitivity to tyrosine kinase inhibitors: A5-01 (2007) (1)
M03-04: Selecting lung cancer patients to targeted therapies based on protein expression by immunohistochemistry (2007) (1)
Gene expression differences in current versus former smokers lung squamous preneoplasia. (2010) (1)
Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer. (2020) (1)
Comprehensive Immune Proﬁling of Medullary Thyroid Cancer (2020) (1)
P2.11-08 Tumor Autoantibody Panel Can Improve the Accuracy of Early Diagnosis in Lung Cancer Presenting with GGNs /Solid Nodules (2018) (1)
Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers. (2016) (1)
CLINICAL BASIS FOR EARLY DETECTION OF LUNG CANCER (1999) (1)
P1.05-001 Creation and Early Validation of Prognostic miRNA Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium: Topic: Translational Research and Biomarkers (2017) (1)
PS06.01 CD44 Confers EMT Phenotypic Change Following Resistance to EGFR-TKIs in Lung Cancer: Topic: Pathology (2017) (1)
Chromosomal aneusomy in sputum predicts for lung cancer in nested case-control study. (2006) (1)
The clinical relevance of recent developments in pathology and biology of small cell lung cancer. (1989) (1)
P3.01-021 Reproducibility of Comprehensive Histologic Assessment and Refining Histologic Criteria in P Staging of Multiple Tumor Nodules: Topic: Morphology (2017) (1)
Analysis of c-erb-1 (EGFR) and c-erb-2 (HER2) expression in bronchial dysplasia: Evaluation of potential targets for chemoprevention of lung cancer. (2006) (1)
MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates (2017) (1)
Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (2016) (1)
[Primary lung cancer in Denmark. Historical and current developmental tendencies]. (1999) (1)
Reply to Waller et al. Standardizing Surgical Treatment for Mesothelioma. (2020) (1)
PL2-02: Molecular staging of lung cancer (2007) (1)
Prognostic significance of EGFR FISH and IHC in non small-cell lung cancer patients treated with chemotherapy alone. (2006) (1)
Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial. (2019) (1)
Abstract A39: Development and validation of an integrated genomic classifier to predict sensitivity to the IGF‐1R/IR tyrosine kinase inhibitor, OSI‐906, in colorectal cancer (2009) (1)
O-191 HER1-HER2-HER3 gene amplification and akt activation inpatients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib (2005) (1)
Tobacco money: up in smoke? (2002) (1)
Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). (2020) (1)
P3-088: Serum E-cadherin does not associate with response to gefitinib in patients with non-small cell lung cancer (NSCLC) (2007) (1)
A randomized phase III trial of adjuvant endocrine therapy with tamoxifen for one year (TAM1) vs tamoxifen for two years (TAM2) in postmenopausal high risk patients with estrogen receptor positive or estrogen receptor unknown breast cancer. A DBCG study (1998) (1)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
Progress in research on screening and genetics in lung cancer. (2014) (1)
Lung cancer chemoprevention - focus on surrogate markers (2005) (1)
16 Randomized trial in small cell lung cancer comparing the combination of cisplatin and carboplatin with carboplatin alone in combination chemotherapy (1997) (1)
A phase 1b/2 trial of dupilumab given in conjunction with PD-(L)1 blockade in the treatment of relapsed/refractory metastatic NSCLC. (2022) (1)
PS01.20: Immune Checkpoints Expression in Small Cell Lung Cancer Lines: Topic: Pathology (2016) (1)
7.1.1 Invited: Chemical Nanoarrays for Early Detection and Screening of Lung Cancer via Volatile Biomarkers (2012) (1)
Synergistic effect of SNDX-275 with lapatinib or erlotinib in breast, lung, or head and neck cancer cell lines expressing HER- 2. (2009) (1)
Preselection of lung cancer cases using FGFR1 mRNA and gene copy number for treatment with ponatinib. (2018) (1)
FISHing for lung cancer: Promising findings using multi-targeted interphase fluorescence in situ hybridization (FISH) for lung cancer detection in sputum (2007) (1)
Abstract 5136: Discovery of novel functional germline variations in the vascular endothelial growth factor receptor 2 gene (KDR) and their effect on gene expression and microvessel density in lung cancer (2011) (1)
Insulin-like growth factor 1 (IGF-1R) protein expression (PE) and gene copy number (GCN) for discrimination of response and outcome to figitumumab in NSCLC. (2012) (1)
HER2 and HER3 genomic gain increases sensitivity to gefitinib in epidermal growth factor receptor positive advanced non-small cell lung cancer (2005) (1)
IGF-1R as a predictive marker for EGFR TKI (Gefitinib) resistance in Non Small Cell Lung Cancer using IHC and AQUA technology (2011) (1)
Serum E-cadherin does not associate with response to gefitinib in patients with non-small cell lung cancer (NSCLC): P3-088 (2007) (1)
MHC class II in lung cancer (2016) (1)
OX40/OX40L protein expression in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers (2019) (1)
MA21.03 The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer (2019) (1)
Squamous cell lung cancer: where do we stand and where are we going? (2013) (1)
P2.04-15 Heterogeneity and Correlation Between Immune Markers in Lung Cancers: Analysis of Treatment-Naïve Lesions (2018) (1)
Predictive value and reproducibility of immunoreactive antibodies (1995) (1)
First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP. (2018) (1)
O-131 High prevalence of endobronchial malignancy in high-risk patients who have moderate dysplasia in sputum (2003) (1)
A randomized, double-blind, multicenter phase 2 trial of denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer. (2014) (1)
Proposal for WHO histological typing of lung tumors: Adenocarcinoma and related tumors (1997) (1)
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study of Onartuzumab (METMAB) in Combination with Paclitaxel + Cisplatin (or Carboplatin) as First-Line Treatment for Patients (PTS) With Stage IIIB or IV Squamous Non-Small Cell Lung Cancer (NSCLC) (2012) (1)
Fucosyl-GM1 in small-cell lung cancer. A comparison with the tumour marker neuron-specific enolase. (1994) (1)
Diagnosis of abominal metastases in small cell carcinoma of the lung : A prospective study of computer tomography and ultrasonography (1992) (1)
P2.03b-048 Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer (2017) (1)
The role of IGF-1R in EGFR TKI resistance in NSCLC using IHC and AQUA technology. (2011) (1)
International association for the study of lung cancer Pathology Committee: Report from the meetings held at the IV World Congress on Lung Cancer, Toronto 1985 (1985) (1)
1330TiPA PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER TRIAL OF DENOSUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER. (2014) (1)
Biology of Lung Cancer (1988) (1)
Small-cell lung cancer--the clinical relevance of the histopathological classification and some biological aspects. (1987) (0)
P35.09 Oncogenetic Differences in Never-Smokers versus Smokers with NSCLC Adenocarcinoma Treated at the Mt Sinai Tisch Cancer Institute (2021) (0)
Evaluation of chromosomal aneusomy in bronchial epithelium of smokers as a marker for lung cancer risk. (2004) (0)
Abstract 3637: Expression of an immune checkpoint- Poliovirus Receptor (PVR) in small cell lung cancer (2018) (0)
PD2-3-6: ERBB3 expression correlates with vorinostat and gefitinib activity and its co-expression with E-cadherin restores response to gefitinib in NSCLC (2007) (0)
A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers (2021) (0)
P2.02-070 C-MET as a Biomarker in Patients with Surgically Resected Non-Small Cell Lung Cancer (2017) (0)
PD-057 Increased expression of C-erb-B1 (EGF-R) but not C-erb-B2 (HER2) is associated with dysplastic change in bronchial airways: Correlation with increased 1,067, MCM2 and P53 expression (2005) (0)
P2.13-01 Low EV miR-30c Levels as Biomarker of Increased Tumor Autophagy and Chemoradiotherapy Resistance in Locally Advanced NSCLC (2022) (0)
Abstract 5439: Characterization of the class 1 histone deacetylase inhibitor entinostat in EGFRi acquired resistance models and in combination with cetuximab in NSCLC (2010) (0)
The selection of the optimal target population for spiral CT screening and chemoprevention trials (2006) (0)
E28. Chemoprevention of lung cancer: Intermediate endpoints for chemoprevention trials (2005) (0)
Abstract LB-90: Oral iloprost improves endobronchial dysplasia in former smokers (2011) (0)
Commentary (Dziadziuszko/Hirsch): EGFR Inhibitors in Lung Cancer (2005) (0)
Abstract 3636: The immune checkpoint, HVEM, is associated with PDL1 expression in lung cancer cell lines (2018) (0)
P2.03-019 Sizing Capillary Electrophoresis with PCR to Detect Various EGFR Exon 19 Deletions in Non-Small Cell Lung Cancer (2017) (0)
Effects of entinostat onresistance to cetuximab and EGFR TKIs in non-small cell lung cancer. (2012) (0)
Enzastaurin (LY317615.HCl) inhibits human lung cancer cells in vitro and in vivo: a pharmacodynamic study (2007) (0)
Combined EGFR targeted therapy in a novel in vivo pancreas cancer model (2007) (0)
Methods for predicting clinical outcome for inhibitors of epidermal growth factor receptor for cancer patients (2005) (0)
Study Shows VATs Partial Pleurectomy Improves Quality of Life for Malignant Mesothelioma Patients (2013) (0)
335 mTOR Inhibitor CC-223 Acts in Synergy with Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Non-Small Cell Lung Cancer Cell Lines (2012) (0)
P-245 245 Detection of RNA biomarkers in sputum of lung cancer patientsand high risk smokers (2005) (0)
Abstract CT199: Rescuing response to ICI by blocking the type-2 immune axis in patients with NSCLC progressing on immunotherapy: A phase 1b/2 trial of dupilumab administered with checkpoint blockade (2023) (0)
Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribution (2020) (0)
Zeroing in on Non-Small Cell Lung Cancer : Integrating Targeted Therapies into Practice (2009) (0)
Abstract 1492: Histological and molecular characteristics of 29 cases of carcinomain situfrom a prospective bronchoscopic cohort (2010) (0)
Pneumonological workshop Under the auspices of “ Polish Pneumonology and Allergology ” (0)
353 Protein expression for receptor activator of NFkB (RANK) and its ligand (RANKL) in non-small cell lung cancer (NSCLC) (2014) (0)
P68.12 Inter-Tumor Heterogeneity of CD44 Expression in Non-Small Cell Lung Cancers / EGFR Mutated Lung Adenocarcinomas (2021) (0)
Predictive Biomarkers and Personalized Medicine FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFRTKI Sensitivity across All LungCancer Histologies (2014) (0)
EGFR Amplification in Lung Cancer: Time for Thawing the Frozen FISH? (2016) (0)
Molecular and Cell Biology of Lung Carcinoma (2004) (0)
MINI01.15: Prophylactic Cranial Irradiation (PCI) for Limited Small Cell Lung Cancer (LSCLC): An IASLC Physician Survey: Topic: Radiation Oncology (2016) (0)
PP.48 Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients (2023) (0)
P2.12-05 Cancer and Atopy: Parallel Drivers? IL-4 Blockade Synergizes with PD-L1 Blockade to Reverse Type-2Mediated Immunosuppression (2022) (0)
Abstract 4583: Heterogeneity in immune biomarker expression: Detailed analysis of a case with SCLC transformation after EGFR-TKI treatment (2017) (0)
Summary of EGFR-Biomarker data from the randomized, controlled phase 3 trial SQUIRE on adding Necitumumab to first-line Gemcitabine-Cisplatin (GC) for squamous Non-Small Cell Lung Cancer (sqNSCLC). (2017) (0)
Abstract PL04-02: Oral iloprost for the chemoprevention of lung cancer: A multicenter, SPORE-initiated trial (2011) (0)
OA06.04 Constructing a Global Molecular Database for Thoracic Malignancies: The IASLC Molecular Subcommittee Lung Cancer Dataset (2021) (0)
P-265 Natural history of untreated endobronchial carcinoma in situ (2005) (0)
484 Germline Variants in Angiogenesis Genes as Markers of Progression-free Survival in Stage I-III Non-small Cell Lung Cancer Patients (2012) (0)
The diagnostic puzzle of ALK rearrangement in lung cancer. A novel intron related abnormality (2013) (0)
Abstract B16: Histology and intervention related miRNA expression changes from baseline to follow-up paired bronchial biopsies of patient in the iloprost chemoprevention trial (2012) (0)
Pre-invasive diseases of the lung (2009) (0)
I.17 ALK Genomic Aberrations in NSCLC and Clinical Implications (2019) (0)
Monoclonal antibodies (mabs) for detection of metastatic carcinoma cells in bone marrow of Small Cell Lung Cancer (SCLC) (1991) (0)
E27. The role of fluorescence in situ hybridization as a predictive“marker” for sensitivity to EGFR inhibitors in patients with NSCLC (2005) (0)
[Lung cancer screening--what now?]. (2001) (0)
D2-05: Biomarker analysis of the TRIBUTE Trial of chemotherapy with or without erlotinib in advanced non-small cell lung cancer (NSCLC): FISH positivity predicts outcome (2007) (0)
Abstract 558: Correlations of FGFR1 with ligand signaling in small-cell lung cancer (2015) (0)
Strategies in Patients with Other Molecular Alterations (2015) (0)
783 New EGFR variants around the EGFRvIII region in non-small cell lung cancers(NSCLC) (2003) (0)
Nordic Symposium on Lung Cancer 1992 — A report (1993) (0)
29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC) (2022) (0)
EP1.04-15 NSCLC Response Determinants to Chemoimmunotherapy: Deep Profiling of Tumors Following Neoadjuvant Cemiplimab and Chemotherapy (2019) (0)
669 Neuroendocrine (NE) tumors of the lung: Prognostic factors in 152 cases (1997) (0)
Abstract 4550: Correlations between tumor mutation burden, inflammatory profile and histological characteristics of tumor microenvironment in early-stage squamous cell lung carcinoma (2019) (0)
Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study. (2018) (0)
Abstract 5891: Plasma-based BDA-NGS test holds potential in circulating nucleic acid based oncogenic aberration detection (2020) (0)
P2.09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma (2018) (0)
Search for the Standard Model Higgs Boson in the Diphoton Decay Channel with 4.9 fb[superscript -1] of pp Collision Data at √s=7 TeV with ATLAS (2012) (0)
Look Ma--no cancer. (1993) (0)
Incidence and prognosis of lung cancer in Denmark. A population based study of more than 100,000 cases (2000) (0)
Comparison of CISH and FISH for detection of EGFR copy number in lung adenocarcinoma and correlation with EGFR and KRAS mutation status and EGFR immunoreactivity (2008) (0)
Epidermal Growth Factor Receptor Targeted Therapy—Markers of Sensitivity and Response (2016) (0)
Exploratory P hase I II S tudy o f P aclitaxel a nd C isplatin Versus P aclitaxel a nd C arboplatin i n A dvanced O varian Cancer (2000) (0)
Evaluation of CD73 in lung cancer. (2017) (0)
Abstract 2626: Expression of human poliovirus receptor, an immune checkpoint biomarker in lung cancer (2017) (0)
Evaluation of chromosomal aneusomy in bronchial epithelium of smokers as a marker for lung cancer risk (2004) (0)
O.04 Results from the IASLC Global Survey on Molecular Testing in Lung Cancer (2019) (0)
Analysis of real-world data (RWD) on treatment (tx) sequencing in patients with advanced non-small cell lung cancer (aNSCLC). (2019) (0)
Search for new phenomena in events with three charged leptons at sqrt[s]=7 TeV with the ATLAS detector (2013) (0)
23 Validation of PD-L1 dynamic expression on extracellular vesicles as a predictor of response to immune-checkpoint inhibitors and survival in non-small cell lung cancer patients (2021) (0)
Outcomes in bronchial dysplasia: persistence of lesions and associations with development of invasive non-small cell lung cancer: A7-05 (2007) (0)
New Digital Tools Could Improve Treatment for Lung Cancer Patients (2019) (0)
DesignofaPhaseIIIClinicalTrialwithProspectiveBiomarker Validation: SWOG S0819 (2012) (0)
[Male breast cancer. A review]. (1996) (0)
O-049 Affymetrix gene expression profiles in premalignant bronchialmucosa (2005) (0)
Subclassification of small cell lung cancer (SCLC) and significance of non-SCLC with neuroendocrine features (1997) (0)
E-39. Standardization of biomarkers for chemoprevention studies in lung cancer (2003) (0)
Survival benefit of gefitinib treated non-small-cell lung cancer patients with exon 19 deletion mutations in epidermal growth factor receptor (EGFR), detected by a new sensitive PCR-based method (2007) (0)
Reproducibility of histopathological evaluation in adenocarcinoma of the lung (1991) (0)
Programmed death ligand 1 testing: is there one best test? (2017) (0)
PP01.08 Circulating Genetically Abnormal Cells Predicts Risk of Lung Cancer in Individuals with Indeterminant Pulmonary Nodules (2023) (0)
Targeted Molecules for Lung Cancer Diagnosis and Therapy (2003) (0)
Abstract 921: Fibroblast growth factor receptor 1 (FGFR1) protein expression and gene copy number in small cell lung cancer (2014) (0)
Abstract B31: Fibroblast growth factor receptor-1 (FGFR1) gene amplification is frequent in lung squamous cell carcinoma and high gene copy number indicates a better prognosis in early stage NSCLC. (2011) (0)
Coordinated over-expression of genes in the EGFR pathway predicts sensitivity to EGFR inhibition in pancreatic cancer (2007) (0)
Access to specialist care and treatment in patients with advanced non-small cell lung cancer. (2016) (0)
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer (2022) (0)
Longitudinal COVID-19 Vaccination-Induced Antibody Responses and Omicron Neutralization in Patients With Lung Cancer. (2022) (0)
Fluorescence In situ Hybridization Subgroup Analysis ofTRIBUTE , a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non ^ Small Cell Lung Cancer (2008) (0)
Bronchial epithelial proliferation measured by Ki-67 is related to current smoking and sex but not to lung cancer or chronic obstructive pulmonary disease: P1-192 (2007) (0)
Umbrella Test the effect of one or more drugs on one or more single mutations in a variety of cancer types Test the impact of different drugs on different mutations in a single type of cancer Basket (2015) (0)
OA01.09 Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer (2019) (0)
P1.12-05 Microenvironment Characterization of Small Cell Lung Cancer Xenografts Implanted in Hematopoietic Humanized Mice (2019) (0)
Abstract 5148: Non-small cell lung cancer expression ofVEGF pathway genes and association with heritable genetic variants (2011) (0)
Subtype-specific transcription factors are clinically relevant and show distinct therapeutic vulnerabilities in human small cell lung cancer (2022) (0)
Prediction of Antitumor Response (2011) (0)
OA19.01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium (2017) (0)
P1.12-09 RNA Sequencing in Small Cell Lung Carcinoma Reveals Change in Neuroendocrine Pattern in Primary Tumor Versus Lymph Node Metastases (2019) (0)
EGFR expression and the flexibility of FLEX. (2012) (0)
SP 134 Predictive and pharmacodynamic markers of susceptibility for targeting IGF-1R receptor (2011) (0)
P2.03b-053 Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab: Topic: Biomarkers (2017) (0)
PD3-1-4: Enzastaurin (LY317615.HCl), a selective PKC beta inhibitor, suppresses human lung cancer cells in vitro and in vivo: a pharmacodynamic study (2007) (0)
Molecular studies support the association between germ-line genetic variants in the vascular endothelial growth factor (VEGF) pathway and survival in non-small cell lung cancer (NSCLC) patients. (2011) (0)
Abstract 798: SeroNet Pooling Project of immunocompromised populations (2023) (0)
EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients (2009) (0)
P1.04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma (2018) (0)
PIK3CA as a prognostic marker in non-small cell lung cancer of squamous cell carcinoma type. (2014) (0)
Assessing lung cancer risk in bronchial dysplasia by identification of prognostic gene expression profiles (2010) (0)
P2.02-011 Clinical and Molecular Features of Lung Cancers with Increased FGFR1 mRNA and/or Gene Copy Number (2017) (0)
EP07.01-001 Molecular Profiling Predicts Outcomes in Patients With Resected Malignant Pleural Mesothelioma (2022) (0)
Molecular marker analysis of SWOG S0636, a phase II trial of erlotinib and bevacizumab in never-smokers with advanced NSCLC. (2012) (0)
Protein expression (PE) and increased IGF1R gene copy number (GCN) in small cell lung cancer (SCLC). (2010) (0)
Update on the use of oral iloprost for the chemoprevention of lung cancer: A7-04 (2007) (0)
Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment (2023) (0)
Epidermal G rowth F actor R eceptor i n N on-Small-Cell L ung Carcinomas: C orrelation B etween G ene C opy N umber a nd Protein E xpression a nd I mpact o n P rognosis (2003) (0)
P3.02b-009 Plasma and Tissue Inflammatory and Angiogenic Biomarkers to Explore Resistance to EGFR-TKIs and Association with VeriStrat Status: Topic: EGFR Biomarkers (2017) (0)
Abstract S01-02: Assessing vulnerability of patients with lung cancer to SARS-CoV-2 infection based on serological antibody analyses (2021) (0)
Recent advances of biomarker research in lung cancer with special reference to new targeted therapies: Status and future challenges (2012) (0)
Search for a heavy Standard Model Higgs boson in the channel H→ZZ→ℓ[superscript +]ℓ[superscript −]q[bar over q] using the ATLAS detector (2011) (0)
OA01.04 Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A (2021) (0)
P2.04-13 The Immune Checkpoint, HVEM Contribute to Immune Escape in Non Small Cell Lung Cancer of Lacking PDL1 Expression (2018) (0)
Different gene expression profiles between current and former smokers in lung squamous carcinogenesis. (2010) (0)
The art of detecting EML4-ALK gene rearrangements in NSCLC patients - Immediate implications for patient care (2013) (0)
PD-056 Clinical update on the phase II trial of oral iloprost in the chemoprevention of lung cancer in high risk patients (2005) (0)
Epidermal Growth Factor Receptor Messenger RNAExpression , Gene Dosage , and Gefitinib Sensitivity in Non ^ Small Cell Lung Cancer (2006) (0)
Abstract 1713: Folylpoly-α-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in advanced non-small cell lung cancer (NSCLC) (2012) (0)
Title : Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer (2013) (0)
Abstract ED01-03: Chemoprevention of lung cancer with prostacyclins or PPAR gamma agonists. (2011) (0)
Insulin-like growth factor receptor 1 (IGFR-1) is signiﬁcantly associated with longer survival in non-small-cell lung cancer patients treated with geﬁtinib (2006) (0)
Abstract A36: Breath Biomarkers in the Post NLST-era for the Discrimination between Malignant from Benign Pulmonary Nodules (2012) (0)
Search for the Higgs boson in the H → WW → ℓvjj decay channel at √s = 7 TeV with the ATLAS detector (2012) (0)
Bone marrow examination in small cell lung cancer. (1987) (0)
Access to biomarker testing in patients with advanced non-small cell lung cancer. (2016) (0)
M06-03: Prediction of benefit from EGFR TKIs by proteomic analysis of pretreatment serum (2007) (0)
Abstract A043: NaPi2b expression in a large surgical non-small cell lung cancer cohort (2019) (0)
Chemotherapy of Advanced Small-Cell Anaplastic Carcinoma (2020) (0)
PCR method for detection of EGFR exon 19 deletion in NSCLC (2007) (0)
Identification of alterations in gene expression that distinguish persistent from regressive bronchial dysplasia (2011) (0)
P2.13-45 SHERLOC: A Phase 2 Study of Seribantumab in Combination with Docetaxel in Patients with Heregulin Positive, Advanced NSCLC (2018) (0)
Antimicrotubule-Platinum Therapy in NSCLS by Histologic Subtypes 628-Introduction (0)
AntitumorActivityof the EpidermalGrowth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non^Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFRMutations but not EGFRProtein Levels (2006) (0)
NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort (2021) (0)
MA16.02 Platinum-Doublets as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis (2021) (0)
Immunohistochemistry detection of epidermal growth factor receptor (EGFR) exons 19 and 21 mutations in non-small cell lung cancer (NSCLC) using novel mutation specific antibodies. (2010) (0)
2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006 (2007) (0)
November--lung cancer awareness month! (2010) (0)
Abstract CT205: A phase I/Ib trial of intratumoral Poly-ICLC in resectable malignant pleural mesothelioma (2022) (0)
Intra- and Interobserver Problems in the Histopathologic Classification of Malignant Lung Tumors (1986) (0)
Abstract B45: Analysis of c‐Met gene copy number by dual‐color silver in situ hybridization (SISH) in non‐small cell lung cancer (NSCLC) (2009) (0)
Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395]. (2022) (0)
Chapter 29: Classification of Lung Cancer Histology by Gold Nanoparticle Sensors (2017) (0)
The TOPICAL study should be more topical! (2013) (0)
B. Driscoll (ed). Lung Cancer. Volume II: Diagnostic and Therapeutic Methods and Reviews (2003) (0)
Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease? (2014) (0)
196PPREVALENCE, PROGNOSTIC SIGNIFICANCE, AND OVERLAP OF ACTIONABLE BIOMARKERS IN NSCLC. (2014) (0)
[Early diagnosis of cancer]. (1999) (0)
MA11.10 Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400) (2021) (0)
IBS15.02 Determinants of Response to ICI (2019) (0)
RECIST measurement through the exhaled breath in lung cancer: Myth or reality? (2014) (0)
EP16.03-029 SLIT2 Expression in NSCLC With Long-Term Response to Pemetrexed (2022) (0)
OA23.07 Analysis of Outcomes in US IRESSA Clinical Access Program (ICAP) Patients on Gefitinib for More Than 10 Years (2017) (0)
Predictive capability of PD-L1 protein expression for patients with advanced NSCLC: Any differences based on histology? (2023) (0)
OA06.03 Serological Response to SARS-CoV-2 Vaccination in Patients Lung Cancer: A Mount Sinai-Led Prospective Matched Controlled Study (2022) (0)
P2-047: Putative biomarker genes for pemetrexed theatment in small and non-small cell lung cancer cell lines, detected by microarray analysis (2007) (0)
Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer (2021) (0)
PP 35 Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer (NSCLC) (2011) (0)
Lung Cancer Prevention (2010) (0)
P-273 The role of Ki67, p53, EGFR, HER2 and CD31 as possible predictive biomarkers for development of lung cancer in a high-risk population (2003) (0)
O-76 Oligonucleotide microarray gene expression profiles of lung cancer cell lines sensitive and resistant to ZD-1839 (2003) (0)
Gene expression differences in current and former smokers in lung squamous preneplasia. (2010) (0)
P3-146: Sensitive PCR method detects EGFR exon19 deletions in NSCLC (2007) (0)
Occurrence ofneuronspecific enolase intumourtissue andserum insmall celllung cancer (1991) (0)
Prediction of response to Gefitinib in NSCLC by EGFR protein expression is increased by a novel antibody and the use of AQUA technology. (2010) (0)
P-264 Ki67 proliferation index in endobronchial biopsies: Associationwith lung cancer, airflow obstruction and smoking history (2005) (0)
Abstract B6: Folylpoly-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in non-small cell lung cancer (NSCLC) (2012) (0)
INTRACRANIAL METASTASES IN SMALL CELL LUNG CANCER. (1982) (0)
PP117 Increased EGFR gene copy number is variably associated with both EGFR and KRAS Mutation (Mt) status and influences Progression Free Survival (PFS) to first-line chemotherapy in EGFR/KRAS wildtype (WT) patients (2009) (0)
P2.03b-035 EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE: Topic: Biomarkers (2017) (0)
P1.03-052 Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism (2017) (0)
MA 05.14 Differential Expression of IFN-Stimulating DNA Sensors STING and cGAS in Lung Cancer Subtypes (2017) (0)
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer (2013) (0)
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer (2019) (0)
SWOG 0709: A randomized phase II “pick-the-winner” trial of erlotinib (ERL) vs. ERL plus carboplatin/paclitaxel (C/T) in patients (pts) with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS 2) as selected by serum proteomics. (2015) (0)
O-197 ERBB3 as predictor of response and target for overcoming resistance to EGFR inhibitors in NSCLC (2005) (0)
[Cytostatic chemotherapy and radiotherapy in small cell anaplastic lung carcinoma. Results of 2 prospective studies]. (1980) (0)
Molecular biomarkers for early detection of lung cancers (2004) (0)
Abstract IA14: Cetuximab in NSCLC and predictive markers (2012) (0)
Role of Lactate in the Regulation of Transcriptional Activity of Breast Cancer-Related Genes and Epithelial-to-Mesenchymal Transition Proteins: A Comparison of MCF7 and MDA-MB-231 Cancer Cell Lines (2023) (0)
SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study). (2020) (0)
Abstract #5397: The HDAC inhibitor SNDX-275 synergizes with erlotinib and induces mesenchymal to epithelial transition in pancreatic carcinoma (2009) (0)
1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients (2022) (0)
Adenocarcinoma of the lung and mesothelioma (1995) (0)
MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma (2017) (0)
OA13.01 SPECS2 Lung Cancer Consortium Prospective Multicenter Validation of Prognostic Signature for Early Stage Squamous Lung Cancer (2019) (0)
MA11.05 Indoleamine 2,3-Dioxygenase Expression in Non-Small-Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact (2018) (0)
Correlation of EGFR Expression by IHC and FISH to Predict Patient Outcome: A Phase II RTOG 0324 Study for Patients with Stage III NSCLC Treated by Chemoradiotherapy and Cetuximab (C225) (2008) (0)
Lung cancer early detection via breath analysis (2015) (0)
Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States (2022) (0)
P-277 A histological model to predict airway response to promising chemoprevention agents in phase II lung cancer prevention trials (2003) (0)
P1.05-027 Novel Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma: A Study by the SPECS Lung Consortium: Topic: Translational Research and Biomarkers (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Fred R. Hirsch?

Fred R. Hirsch is affiliated with the following schools:

Chulalongkorn University
MD Anderson Cancer Center
Kanazawa University
Charles University
University of Colorado Denver
Icahn School of Medicine at Mount Sinai
University of California, Los Angeles
University of Tsukuba
University of Colorado
University of Copenhagen
Tokyo Medical University

Fred R. Hirsch's Academic­Influence.com Rankings

Why Is Fred R. Hirsch Influential?

Fred R. Hirsch's Published Works

Published Works

What Schools Are Affiliated With Fred R. Hirsch?

Fred R. Hirsch's AcademicInfluence.com Rankings